Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 12 Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 3 JAN 25 Annual Reload of MEDLINE database
NEWS 4 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 5 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 6 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 7 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 8 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail Addresses
NEWS 9 APR 02 CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS 10 APR 02 PATDPAFULL: Application and priority number formats enhanced
NEWS 11 APR 02 DWPI: New display format ALLSTR available
NEWS 12 APR 02 New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS 13 APR 02 EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS 14 APR 07 CA/CAplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields
NEWS 15 APR 07 50,000 World Traditional Medicine (WTM) Patents Now Available in CAplus
NEWS 16 APR 07 MEDLINE Coverage Is Extended Back to 1947

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2, AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:08:56 ON 06 MAY 2010

=> file caplus, biosis, embase, medline
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'CAPLUS' ENTERED AT 10:09:27 ON 06 MAY 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:09:27 ON 06 MAY 2010
Copyright (c) 2010 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:09:27 ON 06 MAY 2010
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 10:09:27 ON 06 MAY 2010

=> s (GPC3 or AC002420.1 or DGSX or GTR2-2 or MXR7 or OCI-5 or SDYS or SGB or SGBS or SGBS1 or "glypican 3")
L1 3185 (GPC3 OR AC002420.1 OR DGSX OR GTR2-2 OR MXR7 OR OCI-5 OR SDYS
  OR SGB OR SGBS OR SGBS1 OR "GLYPICAN 3")

=> duplicate remove L1
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS, EMBASE, MEDLINE'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING IS APPROXIMATELY 47% COMPLETE FOR L1
PROCESSING IS APPROXIMATELY 74% COMPLETE FOR L1

PROCESSING COMPLETED FOR L1
L2 1768 DUPLICATE REMOVE L1 (1417 DUPLICATES REMOVED)

=> s L2 and ("skin cancer" or melanoma)
L3 80 L2 AND ("SKIN CANCER" OR MELANOMA)

=> s L2 n ("skin cancer" or melanoma)
MISSING OPERATOR L2 N
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s L2 s ("skin cancer" or melanoma)
MISSING OPERATOR L2 S
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s L2 (n) ("skin cancer" or melanoma)
L4 4 L2 (N) ("SKIN CANCER" OR MELANOMA)

=> duplicate remove L4
PROCESSING COMPLETED FOR L4
L5 4 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)

=> d L5 bib abs 1-4

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2009:1143216 CAPLUS
DN 152:259584
TI Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry study
AU Kandil, Dina; Leiman, Gladwyn; Allegretta, Mark; Evans, Mark
CS USA
SO Cancer (Hoboken, NJ, United States) (2009), 117(4), 271-278
CODEN: CANCAR; ISSN: 0008-543X
PB John Wiley & Sons, Inc.
DT Journal
LA English
AB BACKGROUND: The incidence of melanoma is increasing. Fine-needle aspiration (FNA) is crit. in documenting recurrent/metastatic disease in established cases. The potential of metastatic melanoma (MM) to mimic epithelial tumors presents a diagnostic dilemma. In liver FNA, the distinction between hepatocellular carcinoma (HCC) and MM is a frequent challenge. Glypican-3 (GPC3), a heparan sulfate proteoglycan, is a highly sensitive and specific marker for HCC. Serum GPC3 was shown to be expressed in 40% of primary melanomas (PMs), but to the authors' knowledge no tissue studies to date have assessed GPC3 expression in MM. In this

study, GPC3 protein expression was investigated in FNAs from MM, and in corresponding histol. sections from the primary tumors. METHODS: Sixty archival, direct FNA smears or CytoLyt-fixed samples from 50 patients with MM were retrieved together with formalin-fixed, paraffin-embedded specimens available from 17 corresponding PMs. All cases were stained with anti-GPC3 antibody. FNA and core biopsy specimens from HCCs and benign liver were used as pos. and neg. controls. GPC3 expression was divided into 2 categories: neg. (neg. or weak cytoplasmic staining) and pos. (moderate or strong cytoplasmic with membranous accentuation). RESULTS: All FNAs from MM cases were neg. (0 of 60) for GPC3. The exact 95% Clopper-Pearson confidence interval was 0.0% to 5.96%. Only 1 case of PM (1 of 17; 5.9%) demonstrated weak focal cytoplasmic staining (regarded as neg.). CONCLUSIONS: In the current study, all MM and PM cases in archival FNAs and tissue sections were found to be neg. for GPC3. These data suggest that GPC3 is not expressed in melanoma using the 1G12 clone.

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:216149 CAPLUS

DN 151:144580

TI Glypican-3: A Novel Diagnostic Marker for Hepatocellular Carcinoma and More

AU Kandil, Dina H.; Cooper, Kumarasen

CS Department of Pathology, University of Vermont, Burlington, VT, 05401, USA

SO Advances in Anatomic Pathology (2009), 16(2), 125-129
CODEN: AAPDCK; ISSN: 1072-4109

PB Lippincott Williams & Wilkins

DT Journal; General Review

LA English

AB A review. Glypican-3 (GPC3) is a heparan sulfate proteoglycan that plays an important role in cell growth and differentiation. GPC3 function is tissue dependent. In some tissues, GPC3 acts as a tumor suppressor gene, whereas in others, it acts as an oncofetal protein. Studies have shown that GPC3 is a reliable marker for hepatocellular carcinoma. The sensitivity and specificity exceeds both .alpha.-fetoprotein and hepatocyte-paraffin1. GPC3 immunohistochem. can aid in the differentiation of testicular germ cell tumors, being expressed in all yolk sac tumors but not in seminomas. GPC3 expression has also been identified in some squamous cell carcinomas of the lung and clear cell carcinomas of the ovary. The role of GPC3 in melanomas is still controversial. This article reviews the current information on the application of GPC3 immunostaining in surgical pathol. and cytol.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2006:39388 CAPLUS
DN 144:228826
TI Melanoma antigen gene family D 1 protein as hepatocarcinoma marker and its application in cancer diagnosis
IN Wan, Dafang; Gu, Jianren; Yang, Shengli
PA Shanghai New World Gene Technology Development Co., Ltd., Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 22 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CN 1629637	A	20050622	CN 2003-10109398	20031215
CN 1281962	C	20061025		
PRAI CN 2003-10109398		20031215		

AB This invention relates to melanoma antigen gene family D1 protein (MAGFD1) as hepatocarcinoma marker, test kit and protein chip contg. anti-MAGED1 specific antibody for diagnosing hepatocarcinoma. The protein chip can also contains antibodies against other antigens, such as pTEN, p21, p27, p73, p53, Rb1, APC, nm23, P16, MXR7, IGF-II, TGF.alpha., HGF-R, c-erbB-1, Ras, Raf, c-myc and c-ets-2. This invention also describes medicine contg. antagonist of MAGFD1 and pharmaceutically acceptable carriers.
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:827193 CAPLUS
DN 142:4152
TI Identification of glypican-3 as a novel tumor marker for melanoma
AU Nakatsura, Tetsuya; Kageshita, Toshiro; Ito, Shosuke; Wakamatsu, Kazumasa; Monji, Mikio; Ikuta, Yoshiaki; Senju, Satoru; Ono, Tomomichi; Nishimura, Yasuharu
CS Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
SO Clinical Cancer Research (2004), 10(19), 6612-6621
CODEN: CCREF4; ISSN: 1078-0432
PB American Association for Cancer Research
DT Journal
LA English
AB The authors reported recently the novel tumor marker glypican-3 (GPC3) for

hepatocellular carcinoma. In the present study, the authors investigated the expression of GPC3 in human melanoma cell lines and tissues and asked whether GPC3 could be a novel tumor marker for melanoma. Expression of GPC3 mRNA and protein was investigated in human melanoma cell lines and tissues using reverse transcription-PCR and immunohistochem. anal. Secreted GPC3 protein was quantified using ELISA in culture supernatants of melanoma cell lines and in sera from 91 patients with melanoma and 28 disease-free patients after surgical removal of primary melanoma. All of the subjects were Japanese nationals. In >80% of melanoma and melanocytic nevus, there was evident expression of GPC3 mRNA and protein. Furthermore, GPC3 protein was evidenced in sera of 39.6% (36 of 91) of melanoma patients but not in sera from subjects with large congenital melanocytic nevus (0 of 5) and from healthy donors (0 of 60). Twenty-seven of 36 serum GPC3-pos. patients were neg. for both serum 5-S-cysteinyldopa and melanoma-inhibitory activity, well-known tumor markers for melanoma. The pos. rate of serum GPC3 (39.6%) was significantly higher than that of 5-S-cysteinyldopa (26.7%) and of melanoma-inhibitory activity (20.9%). Surprisingly, the authors detected serum GPC3 even in patients with stage 0 in situ melanoma. The pos. rate of serum GPC3 at stage 0, I, and II (44.4%, 40.0%, and 47.6%) was significantly higher than that of 5-S-cysteinyldopa (0.0%, 8.0%, and 10.0%). Also obsd. was the disappearance of GPC3 protein in sera from 11 patients after surgical removal of the melanoma. GPC3 is apparently a novel tumor marker useful for the diagnosis of melanoma, esp. in early stages of the disorder.

OSC.G 39 THERE ARE 39 CAPLUS RECORDS THAT CITE THIS RECORD (39 CITINGS)

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT